As shown in Figure 7C, the secretion of IL-6 from the myxoma cells was significantly inhibited by the treatment with AG490 (JAK2 inhibitor, 100 μmol/L), piceatannol (STAT1/3 inhibitor, 100 μmol/L), LLL12 (STAT3 inhibitor, 10 μmol/L), and Ly294002 (PI3K/Akt inhibitor, 30 μmol/L) (Figure 7C). Here, STAT3 is linked to myxoma.